Redeye provides an initial take following the release of BICO's Q3 2026 report. Sales came in slightly below our estimate, but a strong gross margin and continued cost control drove adjusted EBITDA well ahead of our expectations. The quarter was flattered by a one-off contribution of SEK135m from the SCIENION supply and license agreements, while EBIT was weighed down by a non-cash impairment of the remaining Biosero goodwill and technology. Alongside the report, BICO launched its new BICO 2030 strategy, which formalises a step away from large-scale integrated lab automation projects and a sharper focus on Precision Biology.
LÄS MER
